A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics
- 12 May 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (6) , 609-615
- https://doi.org/10.1046/j.1365-2125.2003.01813.x
Abstract
Aims Whether chronic dosing with montelukast confers benefit in patients with moderate to severe asthma remains to be fully established. A proof of concept study was performed evaluating putative benefits with montelukast in moderate persistent asthmatics who were taken off inhaled corticosteroids (ICS) and switched to salmeterol. The latter was done to dissociate the effects of montelukast from ICS.Methods Twenty moderate to severe persistent asthmatics completed a randomized double‐blind crossover study. Subjects received montelukast 10 mg daily or placebo for 2 weeks each. This was preceded by a 2‐week run‐in when ICS were discontinued and salmeterol started, and used on a regular basis throughout the study. Measurements were made after run‐in and after both randomized treatments.Results There were no significant sequence effects for responses as to whether placebo or montelukast were given first or second. Methacholine PD20 values after run‐in, first and second placebo were 63 µg, 60 µg and 64 µg, respectively (corresponding to 2, 4 and 6 weeks of ICS washout, respectively). Lung function deteriorated pre vs post run‐in, which was significant (P < 0.05) for FEF25‐75 % predicted. Montelukast conferred significant (P < 0.05) improvements as change from post run‐in compared with placebo in methacholine PD20, FEV1 % predicted, FEF25‐75 % predicted, diurnal peak expiratory flow, symptoms and salbutamol use. For the primary outcome of methacholine PD20, this amounted to a 1.6‐fold difference (95% CI 1.1, 2.5).Conclusions In moderate persistent asthmatics switched from taking ICS to salmeterol alone, adding montelukast conferred significant benefits on all parameters of asthma control. Further studies are indicated to evaluate whether montelukast exhibits additive effects to ICS/long‐acting β2‐adrenoceptor agonist combination inhalers upon clinically important outcomes.Keywords
This publication has 22 references indexed in Scilit:
- Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary diseaseThorax, 2002
- Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidenceBMJ, 2002
- Bronchial Responsiveness to Adenosine 5 ′ -Monophosphate (AMP) and Methacholine Differ in Their Relationship with Airway Allergy and Baseline FEV1American Journal of Respiratory and Critical Care Medicine, 2002
- Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid TherapyChest, 2001
- Leukotriene antagonists and symptom control in chronic persistent asthmaThe Lancet, 2001
- Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trialsThorax, 2000
- Additive Bronchoprotective and Bronchodilator Effects With Single Doses of Salmeterol and Montelukast in Asthmatic Patients Receiving Inhaled CorticosteroidsChest, 2000
- Dose–response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthmaThe American Journal of Medicine, 2000
- Montelukast Added to Inhaled Beclomethasone in Treatment of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1999
- The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthmaEuropean Respiratory Journal, 1999